Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ZEAL 1L maintenance trial of niraparib plus pembrolizumab in advanced non-small cell lung cancer
2023-508443-40-00Phase 3Completed
- Sponsor
- GSK
- Start
- Feb 2024
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 26
01
Overview
Phase 3, randomised, double-blind trial in non-small cell lung cancer (NSCLC) comparing niraparib + pembrolizumab with placebo + pembrolizumab (2 arms). Primary endpoints: Progression-free survival and Overall survival. Started Feb 2024; status: completed.
02
Drugs
niraparibpembrolizumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2023-508443-40-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-508443-40-00.